SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-269787"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-269787" > Temozolomide in Adv...

Temozolomide in Advanced Neuroendocrine Neoplasms : Pharmacological and Clinical Aspects

Koumarianou, Anna (författare)
Attikon Univ Hosp, Hematol Oncol Unit, Dept Internal Med 4, GR-12462 Athens, Greece.
Kaltsas, Gregory (författare)
Natl Tech Univ Athens, Dept Pathophysiol, Endocrine Unit, Athens, Greece.
Kulke, Matthew H. (författare)
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
visa fler...
Öberg, Kjell (författare)
Uppsala universitet,Endokrin Onkologi
Strosberg, Jonathan R. (författare)
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Spada, Francesca (författare)
European Inst Oncol, Gastrointestinal Med Oncol & Neuroendocrine Tumor, IT-20141 Milan, Italy.
Galdy, Salvatore (författare)
European Inst Oncol, Gastrointestinal Med Oncol & Neuroendocrine Tumor, IT-20141 Milan, Italy.
Barberis, Massimo (författare)
European Inst Oncol, Div Pathol, IT-20141 Milan, Italy.
Fumagalli, Caterina (författare)
European Inst Oncol, Div Pathol, IT-20141 Milan, Italy.
Berruti, Alfredo (författare)
Univ Brescia, Dipartimento Specialita Med Chirurg Sci Radiol &, Azienda Osped Spedali Civili, Brescia, Italy.
Fazio, Nicola (författare)
European Inst Oncol, Gastrointestinal Med Oncol & Neuroendocrine Tumor, IT-20141 Milan, Italy.
visa färre...
Attikon Univ Hosp, Hematol Oncol Unit, Dept Internal Med 4, GR-12462 Athens, Greece Natl Tech Univ Athens, Dept Pathophysiol, Endocrine Unit, Athens, Greece. (creator_code:org_t)
2015
2015
Engelska.
Ingår i: Neuroendocrinology. - 0028-3835 .- 1423-0194. ; 101:4, s. 274-288
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Alkylating agents, such as streptozocin and dacarbazine, have been reported as active in neuroendocrine neoplasms (NENs). Temozolomide (TMZ) is an oral, potentially less toxic derivative of dacarbazine, which has shown activity both as a single agent and in combination with other drugs. Nevertheless, its role in NENs has not been well defined. Several retrospective and prospective phase I-II studies have been published describing its use in a variety of NENs. In a retrospective series, the combination of capecitabine and TMZ was reported to be associated with a particularly high tumour response in pancreatic NENs as a first-line treatment. Although in NENs, determination of the CP-nnethylguanineDNA methyltransferase (MGMT) status has been suggested as a predictive biomarker of response, its role still remains investigational, awaiting validation along with the establishment of the optimal detection method. Metronomic schedules have been reported to potentially overcome MGMT-related drug resistance. Toxicity is manageable if well monitored. We reviewed the literature regarding pharmacological and clinical aspects of TMZ, focusing on specific settings of NENs, different schedules, toxicity and safety profiles, and potential predictive biomarkers of response. 

Ämnesord

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Neuroendocrine neoplasms
Pancreatic neuroendocrine neoplasms
Neuroendocrine carcinomas
Ki-67 labelling index
Progression-free survival

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy